15:25 , May 9, 2018 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Cell therapy Peripheral T cells engineered to express tumor-derived TCRs could help treat ovarian cancer. The cells are generated by deriving TCR libraries from frozen tumor samples from ovarian cancer patients, assembling and cloning...
18:47 , Feb 9, 2018 |  BC Week In Review  |  Company News

China-U.S. research collaboration launched

Hong Kong Polytechnic University, the University at Buffalo, Roswell Park Cancer Institute and three universities in southeast China established a consortium to facilitate development in biotechnology and translational medicine. The partnership will focus on cancer,...
22:17 , Feb 5, 2018 |  BC Extra  |  Company News

China-U.S. translational research collaboration launched

Hong Kong Polytechnic University, the University at Buffalo, Roswell Park Cancer Institute and three universities in southeast China established a consortium to facilitate development in biotechnology and translational medicine. The partnership will focus on cancer,...
17:43 , May 5, 2017 |  BioCentury  |  Emerging Company Profile

Third cell’s the charm

Tactiva Therapeutics LLC is aiming to prolong the activity of TCR-based therapies by adding a third cell type that will act as a renewable source of the CD4+ cells necessary to sustain killer T cell...
00:30 , Dec 2, 2016 |  BC Extra  |  Company News

Parker Institute, CRI form neoantigen initiative

The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute (New York, N.Y.) announced a partnership to improve algorithms used to identify cancer neoantigens. Nonprofit organization Sage Bionetworks (Seattle, Wash.) will manage bioinformatics and...
08:00 , Nov 19, 2015 |  BC Innovations  |  Translation in Brief

Unprimed and activated

A team at the Roswell Park Cancer Institute has shown that a subset of CD4+ T cells can be induced to directly bind tumor antigens and slow tumor growth without needing to be primed by...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Company News

OmniSeq, Roswell Park Cancer Institute diagnostic, functional genomics news

OmniSeq LLC , Buffalo, N.Y.   Roswell Park Cancer Institute , Buffalo, N.Y.   Business: Diagnostic, Functional genomics   OmniSeq began its spinout from Roswell Park and will immediately begin commercializing its OmniSeq Precision Medical...
08:00 , Dec 4, 2014 |  BC Innovations  |  Strategy

Merck Encycles through Canada

The first disclosed grant under Merck & Co. Inc. 's Canadian translational initiative will bolster the ability of macrocycle-based Encycle Therapeutics Inc. to conduct lead optimization of its integrin α4b7 inhibitors for inflammatory bowel disease....
07:00 , Aug 4, 2014 |  BioCentury  |  Emerging Company Profile

Encycle: Oral macrocycles

Macrocycle therapies can block protein-protein interactions that are undruggable with small molecules; however, oral availability and cell penetration remain key challenges. Encycle Therapeutics Inc. 's chemistry platform generates drug-like macrocycles against validated targets to treat...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Clinical News

OmniSeq Target regulatory update

Roswell Park said the New York State Department of Health approved the company’s OmniSeq Target test as a genomic test for cancer patients. The molecular diagnostic test uses next-generation sequencing and analyzes 23 cancer-associated genes,...